New triple therapy aims to shrink lung tumors better than current standard
NCT ID NCT07005336
First seen Jan 31, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This study tests whether adding the experimental drug uliledlimab to a standard immunotherapy (sintilimab) and chemotherapy can help people with advanced non-small cell lung cancer live longer without their cancer growing. About 150 adults who have not had prior treatment for their advanced lung cancer will be randomly assigned to receive either the triple combination or the standard double combination. The main goal is to see if the new combination delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Cancer Hospital
Hefei, China
-
Beijing Chest Hospital
Beijing, China
-
Binzhou Medical University Hospital
Binzhou, China
-
Chongqing University Three Gorges Hospital
Chongqing, China
-
First Hospital of Shanxi Medical University
Taiyuan, China
-
General Hospital of Ningxia Medical University
Yinchuan, China
-
Guangxi Medical University Cancer Hospital
Nanning, China
-
Harbin Medical University Cancer Hospital
Ha’erbin, China
-
Hubei Cancer Hospital
Wuhan, China
-
Jiangmen Central Hospital
Jiangmen, China
-
Linyi People's Hospital
Linyi, China
-
Lishui Central Hospital
Lishui, China
-
Shanghai Chest Hospital
Shanghai, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, China
-
Sichuan Cancer Hospital
Chengdu, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, China
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, China
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
-
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
-
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
-
The Second People's Hospital of Neijiang
Neijiang, China
-
The Second People's Hospital of Yibin
Yibin, China
-
Xiangyang Central Hospital
Xiangyang, China
-
Yunan Cancer Hospital
Kunming, China
-
Zhoukou Central Hospital
Zhoukou, China
Conditions
Explore the condition pages connected to this study.